New research sheds light on the effectiveness of existing and developmental Ebola monoclonal antibodies (mAbs) against the emerging 2026 Bundibugyo virus disease (BVD) outbreak. This study utilized structural modeling to analyze how these antibodies interact with the Bundibugyo virus (BDBV), uncovering potential challenges in treatment efficacy.
Scientists meticulously analyzed 44 BDBV genomes from 2007, 2012, and 2026, including a dozen from the current outbreak in the Democratic Republic of Congo (DRC) and Uganda. They pinpointed mutations in these viral sequences and employed advanced structural modeling to map changes in the viral glycoprotein (GP), subsequently predicting the binding stability of various mAbs. The team's computational analysis indicated that mAb114 (Ebanga), an approved monotherapy, might exhibit compromised binding to BDBV due to critical epitope mutations. For Inmazeb, a triple-antibody cocktail, the model suggested that while individual components might struggle alone, their combined action could still effectively target the virus. Crucially, the experimental pan-ebolavirus cocktail MBP134 showed promising results, with both its components targeting highly conserved epitopes, indicating stable binding without structural displacement. These insights underscore the necessity of experimentally validating therapeutic approaches, particularly when facing genetically diverse viral species, to inform and enhance outbreak response strategies in affected regions.
These computational findings provide a robust framework for prioritizing experimental testing and guiding the response to the current BDBV outbreak. The study advocates for urgent validation through binding measurements and neutralization assays using live or pseudoviruses. The results strongly suggest MBP134 and the complete Inmazeb cocktail as prime candidates for such evaluation, emphasizing that their real-world effectiveness against BDBV remains an open question. This proactive scientific inquiry is vital in the ongoing battle against viral diseases, ensuring that medical responses are both timely and precisely targeted.